![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 75.00 | 73.00 | 77.00 | 75.00 | 75.00 | 75.00 | 15,165 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investment Advice | 149k | -7.14M | -0.1082 | -6.93 | 49.49M |
RNS Number:8402Q Celsis International PLC 27 March 2008 CELSIS INTERNATIONAL PLC ("Celsis", "the Company" or "the Group") signs exclusive agreement with Apath LLC 27 March 2008: Celsis International plc, the life sciences products and laboratory services company, today announces that its Celsis In Vitro Technologies (Celsis IVT) division has signed an exclusive global market development agreement with Apath LLC to assist customers in the evaluation of drug candidates for their cytotoxicity and efficacy against the Hepatitis C virus. Celsis' IVT division, which provides in vitro liver cell products and development services to the pharmaceutical and biotechnology industries to reduce the time and cost of drug discovery and development, has signed an agreement with Apath LLC which is based on its intellectual property portfolio relating to the Hepatitis C virus (HCV). Apath LLC is a US based drug discovery company focused on human viral diseases, and its portfolio was developed by its founder Charles M. Rice, Ph.D. and other pioneers in the field. To date, research into potential therapeutics for HCV has been significantly hindered, in part, by the absence of effective in vitro efficacy models in which potential compounds can be evaluated. This unmet need has contributed to the lack of success in the development of treatments for a disease that affects an estimated 200 million people worldwide, four times the prevalence of HIV, the virus that causes AIDS. There are over 100 pharmaceutical and biopharmaceutical companies who have active HCV programmes. This agreement provides these companies with access to a unique cell-based screening programme of their candidate compounds by leveraging Celsis IVT's market presence and in vitro development capabilities with Apath's proprietary technology platforms against the HCV life cycle. Commercial launch of this programme is expected to take place in Q2 of this calendar year with the potential for sizeable incremental revenues to Celsis IVT over the next several years. This agreement not only provides new growth opportunities for Celsis but is consistent with Celsis' position in providing leading technologies to our customers that provide critical information to assist in the drug discovery and development process. Paul D. Olivo, M.D., Ph.D., President and CSO of Apath LLC, commented: "We are delighted to be working with Celsis and are confident that our expertise in virology and molecular biology and Celsis' leadership and depth of understanding in the drug discovery and development market place will be a successful partnership. We therefore look forward to entering into this agreement where our technology and proprietary know-how will assist in developing a new screening method for the Hepatitis C virus." Jay LeCoque, Chief Executive Officer of Celsis, said: "This market development agreement with Apath LLC is another significant step for our Celsis IVT business and demonstrates the substantive progress that Celsis is delivering to this field. We are pleased to partner with Apath who have assembled a leading intellectual property portfolio in supporting the pharmaceutical and biotechnology industries in their quest to find solutions to treat or prevent Hepatitis C." Enquiries: Celsis International plc Tel: 01223 598 428 Jay LeCoque, Chief Executive Officer Christian Madrolle, Finance Director and Company Secretary Financial Dynamics Tel: 020 7831 3113 Ben Atwell David Yates Notes to editors Celsis International plc Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas; rapid detection, analytical and drug development services and ADME-Tox in vitro technologies. The company is listed on the London Stock Exchange (CEL.L) Each division of Celsis International plc has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market. Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical and biopharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry and biological sciences to stability storage and testing. Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical and biotechnology industries. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly metabolised by the human liver. Further information can be found on its website at www.celsis.com. Apath LLC Apath LLC is a privately held pharmaceutical discovery company, with a focus on the application of state-of-the-art molecular virology and viral genetics in the discovery and development of therapeutics for human viral diseases. Apath was founded in St. Louis, Missouri in 1997 by Charles M. Rice, Ph.D. Dr. Rice is the Maurice R. and Corinne P. Greenberg Professor of Molecular Virology, Viral Pathogenesis, Vaccine Development and Director of the Laboratory of Virology and Infectious Disease at The Rockefeller University as well as the Scientific and Executive Director, Center for the Study of Hepatitis C, A Cooperative Endeavor of The Rockefeller University, Weill Cornell Medical College and New York Presbyterian Hospital. This information is provided by RNS The company news service from the London Stock Exchange END AGRFKAKPPBKDPNB
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions